Defining the roles of hnRNP family members in Acute Myeloid Leukaemia, with a focus on hnRNPA0 and hnRNPA3
No Thumbnail Available
Date
2026
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Saudi Digital Library
Abstract
Acute myeloid leukaemia (AML) is a biologically heterogeneous malignancy characterised by
genetic, epigenetic, transcriptional, and clinical diversity. Patients with AML have variable
treatment responses and high relapse rates and therefore have a significant unmet clinical need
regarding the availability of targeted therapies for all AML subtypes. While recurrent
transcription factor alterations and oncogenic signalling pathways have been extensively
studied, the contribution of post transcriptional gene regulation to AML pathobiology remains
less well defined.
RNA binding proteins, including members of the heterogeneous nuclear ribonucleoprotein
(hnRNP) family, play central roles in coordinating mRNA stability, processing, and translation,
enabling dynamic adaptation to cellular stress and differentiation cues. Here, analysis of
nuclear proteomic data revealed a coordinated reduction in multiple heterogeneous nuclear
ribonucleoproteins (hnRNP) in AML blasts, key regulators of mRNA processing, transport,
and stability. Using publicly available mRNA data sets, this study examined the expression of
hnRNPs family members during normal haematopoiesis and in AML patient blasts.
hnRNPA0 and hnRNPA3 were prioritised for functional investigation. Functional studies using
shRNA and CRISPR-Cas9 to reduce hnRNPA3 expression did not significantly impair the
growth or survival of THP1 AML cells. In contrast, reduced hnRNPA0 expression in KG1a
cells resulted in a marked reduction in cell growth and viability, as assessed by flow cytometry.
This growth impairment was accompanied by a redistribution of the cell cycle, with an
increased proportion of cells accumulating in the G₂/M phase.
Further, an increase in apoptosis was observed using flow cytometry and Appotracker. To
define the molecular programmes governed by hnRNPA0 to allow AML cells to survive RNA
sequencing was performed in KG1a cells where hnRNPA0 was knocked down. Using a
combination of gene ontology, KEGG and GSEA analysis, several pathways characterised by
coordinated suppression of proliferative networks, including E2F regulated and G2/M
checkpoint programmes were changed. In addition, an enrichment of stress responsive and
apoptotic pathways were identified. Among the most prominently upregulated transcripts was
the pro apoptotic effector BCL2L11 (BIM), suggesting hnRNPA0 knockdown may mediate
AML cell survival by suppressing BIM expression. To support this data in an AML cell line,
analysis of mRNA AML patient blasts demonstrated an inverse relationship between hnRNPA0
and BCL2L11 expression, supporting the relevance of hnRNPA0 dependent transcriptional
programmes beyond in vitro models.
In conclusion, this work positions hnRNPA0 as a post transcriptional regulator that sustains
AML cell survival by maintaining proliferative and stress adaptive gene expression
programmes. Rather than acting as a classical oncogenic driver, hnRNPA0 appears to modulate
apoptosis.
Description
Acute myeloid leukaemia (AML) remains a highly aggressive haematological malignancy characterised by poor treatment responses and high relapse rates, highlighting a substantial unmet clinical need for effective targeted therapies across AML subtypes. While recurrent transcription factor alterations and oncogenic signalling pathways have been extensively investigated, the contribution of post-transcriptional gene regulation to AML pathobiology remains less well defined.
RNA-binding proteins, particularly members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, are key regulators of mRNA processing, stability, and translation, enabling cells to dynamically respond to stress and differentiation signals. Nuclear proteomic analysis revealed a coordinated reduction of multiple hnRNP proteins in AML blasts. Subsequent interrogation of publicly available transcriptomic datasets examined the expression patterns of hnRNP family members during normal haematopoiesis and in AML patient samples.
Two candidates, hnRNPA0 and hnRNPA3, were prioritised for functional characterisation. Genetic depletion of hnRNPA3 using shRNA and CRISPR-Cas9 approaches did not significantly affect proliferation or survival in THP1 AML cells. In contrast, hnRNPA0 knockdown in KG1a cells resulted in reduced cell growth and viability, accompanied by cell-cycle redistribution with accumulation in the G₂/M phase and increased apoptosis.
RNA-sequencing analysis of hnRNPA0-depleted cells revealed suppression of proliferative pathways, including E2F-regulated and G2/M checkpoint programmes, alongside enrichment of stress-responsive and apoptotic pathways. Notably, the pro-apoptotic effector BCL2L11 (BIM) was significantly upregulated. Analysis of AML patient transcriptomic datasets demonstrated an inverse correlation between hnRNPA0 and BCL2L11 expression, supporting the clinical relevance of this regulatory axis.
Collectively, these findings identify hnRNPA0 as a post-transcriptional regulator that supports AML cell survival by maintaining proliferative and stress-adaptive gene expression programmes and by suppressing pro-apoptotic signalling.
Keywords
AML, RNA Binding Protein, hnRNPA0, hnRNPA3, Post transcriptional regulation, RNAseq, Apoptosis, Cell Cycle, BCL2L11(BIM), Cancer Biology
